Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
TB Alliance Sublicenses Promising Anti-tuberculosis Drug from the Medicines Patent Pool

On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP's license for the treatment signed with patent holder The Johns Hopkins University in January.

Published
24 March 2017
From
Yahoo Finance
New Tuberculosis Drugs May Become Ineffective: Study

New antibiotics that could treat tuberculosis may rapidly become ineffective, according to new research published by the Lancet ahead of World Tuberculosis Day. The rise in multi-drug resistant tuberculosis, which affected 480,000 people in 2015, could mean that even newly discovered drugs will soon be useless, the study found.

Published
24 March 2017
From
Inter Press Service
Rise of superbug tuberculosis hampers global control efforts

Rising rates of superbug tuberculosis (TB) are threatening to derail decades of progress against the contagious disease, experts said on Thursday, and new drugs powerful enough to treat them are few and far between.

Published
23 March 2017
From
Reuters
TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?

While the unveiling of a list highlighting the need to fund drug development against specific pathogens represented just a beginning for some antimicrobial resistance fighting efforts, the list represented a setback for TB drug development, advocates say.

Published
02 March 2017
From
Science Speaks
New tuberculosis therapy could be more potent than current treatments

Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.

Published
26 January 2017
From
UCLA
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.

Published
26 January 2017
From
MSF Access Campaign
The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical development of tuberculosis (TB) drug candidate sutezolid. The antibiotic sutezolid has long been considered a promising investigational treatment that, if further developed in combination with other drugs, could be used to more effectively treat both drug-sensitive and drug-resistant TB in patients.

Published
25 January 2017
From
Medicines Patent Pool
Indian Woman Wins Right to Use Last-Resort Tuberculosis Drug

An 18-year-old woman and her family have won a battle in an Indian court to gain access to a restricted tuberculosis drug that her doctors say she needs to survive.

Published
24 January 2017
From
Wall Street Journal (blog)
Person-to-person contact may cause most drug-resistant TB cases

The worst form of drug-resistant tuberculosis isn't just arising from inadequate treatment, it's mostly being spread from person to person, according to a new study of hundreds of cases in South Africa.

Published
23 January 2017
From
Reuters
Early data indicates new regimen represents reprieve for patients with XDR TB

Data from an ongoing trial presented today indicates patients with extensively drug resistant tuberculosis for whom other treatments had failed, showed signs of full recovery from disease following a six-month regimen of two new tuberculosis drugs and one repurposed drug.

Published
31 October 2016
From
Science Speaks
← First12345...19Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.